Minoryx Therapeutics, a biotechnology company and CataloniaBio & HealthTech member, has announced positive results of the Phase II/III clinical trial on its main drug, leriglitazone, in patients with adrenomyeloneuropathy (AMN).

“AMN is a rare disease with a great unmet medical need and without any approved treatments currently. The Minoryx clinical trial is a great milestone for this indication” notes Minoryx Chief Medical Officer Uwe Meya.

ADVANCE is a multi-centre, double-blind, placebo-controlled study that took place in hospitals in the United States and Europe, with 116 male patients over 2 years.

Minoryx will begin conversations with the regulatory agencies.

More information

Photo: from left to right, Marc Martinell, CEO of Minoryx, and Uwe Meya, CMO of Minoryx - © Minoryx Therapeutics

You may also be interested in:

• Minoryx gets €25-million loan from European Investment Bank
• Minoryx and Chinese firm Sperogenix enter into an exclusive license agreement for leriglitazone
• Minoryx begins a phase II clinical trial with leriglitazone for the treatment of cALD